Cartiva Synthetic Cartilage Implant

The Cartiva Synthetic Cartilage Implant litigation, centralized before Judge Kristine G. Baker in the Eastern District of Arkansas in February 2026, consolidates claims that the synthetic cartilage implant device — typically used to treat big-toe joint arthritis — fails or degrades after implantation, requiring revision surgery. With just 21 total actions filed roughly seven months after centralization, this is one of the youngest and smallest active federal MDLs, meaning there is no bellwether track record, general-causation ruling, or settlement framework to price against yet.

Funding decisions at this stage rest almost entirely on individual claim documentation: implant date, the specific nature of the device failure or degradation, and whether revision surgery confirmed the alleged defect. Because the claim population is still small, portfolio-style diversification offers less benefit here than in a larger mass tort, so funding is more naturally structured around individual claims or small groupings with strong device-failure documentation rather than a broad portfolio facility.

Medical-lien exposure should still be tracked carefully even at this early stage — revision foot and ankle surgery is a real cost driver, and any insurer or provider liens tied to that care will need to be accounted for in any eventual recovery. Given the docket's youth, funding terms should be structured for a longer expected duration than a mature mass tort would require, with pricing anchored to the strength of individual medical and device records. Criterica Capital's mass tort finance product is the relevant path for claims tied to this litigation as it develops, and a structural brief on the docket's early formation is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.